Does the media refer more to MRNA or CRSP?

In the previous week, Moderna had 15 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 21 mentions for Moderna and 6 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.64 beat Moderna's score of 0.55 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 8 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MRNA or HOOD?

In the previous week, Robinhood Markets had 34 more articles in the media than Moderna. MarketBeat recorded 55 mentions for Robinhood Markets and 21 mentions for Moderna. Robinhood Markets' average media sentiment score of 0.78 beat Moderna's score of 0.55 indicating that Robinhood Markets is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 8 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Robinhood Markets 23 Very Positive mention(s) 11 Positive mention(s) 16 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, MRNA or NVAX?

Novavax has lower revenue, but higher earnings than Moderna. Novavax is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $1.94B 14.29 -$2.82B -$8.15 N/A Novavax $1.12B 1.38 $440.30M -$0.58 N/A

Is MRNA or NVAX more profitable?

Novavax has a net margin of -14.73% compared to Moderna's net margin of -143.55%. Novavax's return on equity of -14.82% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -143.55% -26.64% -19.32% Novavax -14.73% -14.82% 1.23%

Does the media prefer MRNA or NVAX?

In the previous week, Moderna had 14 more articles in the media than Novavax. MarketBeat recorded 21 mentions for Moderna and 7 mentions for Novavax. Moderna's average media sentiment score of 0.55 beat Novavax's score of -0.07 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 8 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novavax 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher valuation & earnings, MRNA or OCGN?

Ocugen has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $1.94B 14.29 -$2.82B -$8.15 N/A Ocugen $4.41M 117.45 -$67.85M -$0.24 N/A

Is MRNA or OCGN more profitable?

Moderna has a net margin of -143.55% compared to Ocugen's net margin of -1,192.18%. Moderna's return on equity of -26.64% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -143.55% -26.64% -19.32% Ocugen -1,192.18% -127,987.80% -135.48%

Does the media prefer MRNA or OCGN?

In the previous week, Moderna had 16 more articles in the media than Ocugen. MarketBeat recorded 21 mentions for Moderna and 5 mentions for Ocugen. Moderna's average media sentiment score of 0.55 beat Ocugen's score of 0.42 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 8 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ocugen 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer REGN or MRNA?

In the previous week, Moderna had 1 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 21 mentions for Moderna and 20 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 1.14 beat Moderna's score of 0.55 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 12 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 8 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Moderna (MRNA) Competitors

$70.03 +0.33 (+0.47%)

Closing price 04:00 PM Eastern

Extended Trading

$69.81 -0.22 (-0.32%)

As of 07:59 PM Eastern

Compare

MRNA vs. CRSP, HOOD, NVAX, OCGN, and REGN

Should you buy Moderna stock or one of its competitors? MarketBeat compares Moderna with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Moderna include CRISPR Therapeutics (CRSP), Robinhood Markets (HOOD), Novavax (NVAX), Ocugen (OCGN), and Regeneron Pharmaceuticals (REGN).

How does Moderna compare to CRISPR Therapeutics?

Moderna (NASDAQ:MRNA) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

CRISPR Therapeutics has lower revenue, but higher earnings than Moderna. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	14.29	-$2.82B	-$8.15	N/A
CRISPR Therapeutics	$3.51M	1,499.92	-$581.60M	-$6.22	N/A

In the previous week, Moderna had 15 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 21 mentions for Moderna and 6 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.64 beat Moderna's score of 0.55 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	8 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Moderna presently has a consensus price target of $37.13, suggesting a potential downside of 46.98%. CRISPR Therapeutics has a consensus price target of $67.78, suggesting a potential upside of 24.17%. Given CRISPR Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CRISPR Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58

Moderna has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market.

75.3% of Moderna shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 4.1% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Moderna has a net margin of -143.55% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

Summary

CRISPR Therapeutics beats Moderna on 10 of the 16 factors compared between the two stocks.

How does Moderna compare to Robinhood Markets?

Moderna (NASDAQ:MRNA) and Robinhood Markets (NASDAQ:HOOD) are related large-cap companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

In the previous week, Robinhood Markets had 34 more articles in the media than Moderna. MarketBeat recorded 55 mentions for Robinhood Markets and 21 mentions for Moderna. Robinhood Markets' average media sentiment score of 0.78 beat Moderna's score of 0.55 indicating that Robinhood Markets is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	8 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Robinhood Markets	23 Very Positive mention(s)	11 Positive mention(s)	16 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Moderna has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, Robinhood Markets has a beta of 2.35, indicating that its stock price is 135% more volatile than the broader market.

Robinhood Markets has a net margin of 41.12% compared to Moderna's net margin of -143.55%. Robinhood Markets' return on equity of 21.39% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Robinhood Markets	41.12%	21.39%	4.73%

Robinhood Markets has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Robinhood Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	14.29	-$2.82B	-$8.15	N/A
Robinhood Markets	$4.47B	20.19	$1.88B	$2.07	48.44

75.3% of Moderna shares are owned by institutional investors. Comparatively, 93.3% of Robinhood Markets shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 20.0% of Robinhood Markets shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Moderna presently has a consensus target price of $37.13, indicating a potential downside of 46.98%. Robinhood Markets has a consensus target price of $114.35, indicating a potential upside of 14.03%. Given Robinhood Markets' stronger consensus rating and higher possible upside, analysts plainly believe Robinhood Markets is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
Robinhood Markets	0 Sell rating(s)	5 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Robinhood Markets beats Moderna on 15 of the 15 factors compared between the two stocks.

How does Moderna compare to Novavax?

Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

Moderna has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, Novavax has a beta of 2.45, indicating that its stock price is 145% more volatile than the broader market.

75.3% of Moderna shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 1.6% of Novavax shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Novavax has a net margin of -14.73% compared to Moderna's net margin of -143.55%. Novavax's return on equity of -14.82% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Novavax	-14.73%	-14.82%	1.23%

Moderna currently has a consensus price target of $37.13, indicating a potential downside of 46.98%. Novavax has a consensus price target of $13.00, indicating a potential upside of 38.00%. Given Novavax's stronger consensus rating and higher probable upside, analysts clearly believe Novavax is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.22

Novavax has lower revenue, but higher earnings than Moderna. Novavax is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	14.29	-$2.82B	-$8.15	N/A
Novavax	$1.12B	1.38	$440.30M	-$0.58	N/A

In the previous week, Moderna had 14 more articles in the media than Novavax. MarketBeat recorded 21 mentions for Moderna and 7 mentions for Novavax. Moderna's average media sentiment score of 0.55 beat Novavax's score of -0.07 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	8 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novavax	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Novavax beats Moderna on 9 of the 15 factors compared between the two stocks.

How does Moderna compare to Ocugen?

Moderna (NASDAQ:MRNA) and Ocugen (NASDAQ:OCGN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

Moderna presently has a consensus price target of $37.13, indicating a potential downside of 46.98%. Ocugen has a consensus price target of $9.50, indicating a potential upside of 520.92%. Given Ocugen's stronger consensus rating and higher possible upside, analysts clearly believe Ocugen is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Moderna has a net margin of -143.55% compared to Ocugen's net margin of -1,192.18%. Moderna's return on equity of -26.64% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Ocugen	-1,192.18%	-127,987.80%	-135.48%

Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, Ocugen has a beta of 2.19, suggesting that its share price is 119% more volatile than the broader market.

In the previous week, Moderna had 16 more articles in the media than Ocugen. MarketBeat recorded 21 mentions for Moderna and 5 mentions for Ocugen. Moderna's average media sentiment score of 0.55 beat Ocugen's score of 0.42 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	8 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocugen	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

75.3% of Moderna shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 4.0% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Ocugen has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	14.29	-$2.82B	-$8.15	N/A
Ocugen	$4.41M	117.45	-$67.85M	-$0.24	N/A

Summary

Moderna beats Ocugen on 8 of the 15 factors compared between the two stocks.

How does Moderna compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Regeneron Pharmaceuticals currently has a consensus price target of $792.65, indicating a potential upside of 27.12%. Moderna has a consensus price target of $37.13, indicating a potential downside of 46.98%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.73
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Moderna's net margin of -143.55%. Regeneron Pharmaceuticals' return on equity of 13.16% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%
Moderna	-143.55%	-26.64%	-19.32%

In the previous week, Moderna had 1 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 21 mentions for Moderna and 20 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 1.14 beat Moderna's score of 0.55 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	12 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	8 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	4.60	$4.50B	$41.04	15.19
Moderna	$1.94B	14.29	-$2.82B	-$8.15	N/A

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Regeneron Pharmaceuticals has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

Summary

Regeneron Pharmaceuticals beats Moderna on 12 of the 16 factors compared between the two stocks.

Get Moderna News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRNA vs. The Competition

Export

Metric	Moderna	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$27.66B	$3.63B	$6.76B	$12.58B
Dividend Yield	N/A	2.21%	2.66%	6.21%
P/E Ratio	N/A	21.26	27.33	24.89
Price / Sales	14.29	347.13	564.67	115.02
Price / Cash	N/A	62.10	29.14	36.96
Price / Book	3.16	8.74	11.01	6.56
Net Income	-$2.82B	$23.81M	$3.57B	$336.70M
7 Day Performance	14.80%	3.64%	2.56%	3.31%
1 Month Performance	48.40%	1.64%	0.89%	1.68%
1 Year Performance	153.82%	69.47%	36.84%	31.96%

Moderna Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRNA Moderna	1.1064 of 5 stars	$70.03 +0.5%	$37.13 -47.0%	+156.6%	$27.66B	$1.94B	N/A	4,700
CRSP CRISPR Therapeutics	2.6222 of 5 stars	$56.80 +3.4%	$67.78 +19.3%	+18.7%	$5.46B	$1M	N/A	460	Analyst Upgrade
HOOD Robinhood Markets	4.3422 of 5 stars	$102.30 +3.7%	$114.41 +11.8%	+22.6%	$91.72B	$4.47B	49.21	2,900	Trending News Analyst Forecast
NVAX Novavax	1.7532 of 5 stars	$9.12 +2.6%	$13.00 +42.6%	+46.9%	$1.50B	$1.12B	N/A	1,990
OCGN Ocugen	2.1804 of 5 stars	$1.67 +11.0%	$9.50 +470.6%	+69.7%	$563.64M	$4.41M	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRNA) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Moderna (MRNA) Competitors

MRNA vs. CRSP, HOOD, NVAX, OCGN, and REGN

How does Moderna compare to CRISPR Therapeutics?

Summary

How does Moderna compare to Robinhood Markets?

Summary

How does Moderna compare to Novavax?

Summary

How does Moderna compare to Ocugen?

Summary

How does Moderna compare to Regeneron Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRNA vs. The Competition

Moderna Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Moderna (MRNA) Competitors

MRNA vs. CRSP, HOOD, NVAX, OCGN, and REGN

How does Moderna compare to CRISPR Therapeutics?

Which has better valuation & earnings, MRNA or CRSP?

Does the media refer more to MRNA or CRSP?

Do analysts prefer MRNA or CRSP?

Which has more risk & volatility, MRNA or CRSP?

Do insiders & institutionals hold more shares of MRNA or CRSP?

Is MRNA or CRSP more profitable?

Summary

How does Moderna compare to Robinhood Markets?

Does the media prefer MRNA or HOOD?

Which has more risk and volatility, MRNA or HOOD?

Is MRNA or HOOD more profitable?

Which has higher valuation & earnings, MRNA or HOOD?

Do institutionals & insiders have more ownership in MRNA or HOOD?

Do analysts prefer MRNA or HOOD?

Summary

How does Moderna compare to Novavax?

Which has more risk & volatility, MRNA or NVAX?

Do insiders & institutionals have more ownership in MRNA or NVAX?

Is MRNA or NVAX more profitable?

Do analysts rate MRNA or NVAX?

Which has stronger earnings and valuation, MRNA or NVAX?

Does the media prefer MRNA or NVAX?

Summary

How does Moderna compare to Ocugen?

Do analysts rate MRNA or OCGN?

Is MRNA or OCGN more profitable?

Which has more volatility and risk, MRNA or OCGN?

Does the media prefer MRNA or OCGN?

Do institutionals & insiders have more ownership in MRNA or OCGN?

Which has higher valuation & earnings, MRNA or OCGN?

Summary

How does Moderna compare to Regeneron Pharmaceuticals?

Do analysts rate REGN or MRNA?

Is REGN or MRNA more profitable?

Does the media prefer REGN or MRNA?

Which has preferable earnings and valuation, REGN or MRNA?

Do institutionals and insiders have more ownership in REGN or MRNA?

Which has more risk & volatility, REGN or MRNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRNA vs. The Competition

Moderna Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools